Short Squeeze Setup — velZ +0.66 · age 4w×1.00 · 2.50%
Founder-Led — founder/CEO led
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal n… Read full Trend Edge analysis →
Sector: Healthcare
Industry: Biotechnology
Exchange: NASDAQ
IPO Date: April 2, 1991
Headquarters: 777 Old Saw Mill River Road, Tarrytown, NY, United States, 10591-6707
Founder-Led: Yes — Leonard Schleifer (Co-Founder, President, CEO & Co-Chairman), George Yancopoulos (Co-Founder, President, Chief Scientific Officer & Co-Chairman)
Key Metrics
Current Price
$781.49
Market Cap
$81.67B
Float
95.8M
Shares Outstanding
101.1M
P/E (Forward)
14.62
P/E (TTM)
20.00
Price/Sales (TTM)
5.26
vs. Analyst Target
+8.7% to analyst PT
Profit Margin
27.87%
Operating Margin (TTM)
33.11%
Revenue (TTM)
$15.53B
Earnings Growth (YoY)
-4.50%
Dividend Rate
3.8%
Analyst Target Price
$849.32 (25 analysts)
Financial History
Annual Revenue & Earnings History
Year
Revenue
Net Income
Gross Profit
EBITDA
2020
$8.50B
$3.51B
$7.14B
$4.10B
2021
$16.07B
$8.08B
$13.35B
$9.67B
2022
$12.17B
$4.34B
$10.47B
$5.26B
2023
$13.12B
$3.95B
$12.23B
$4.05B
2024
$14.20B
$4.41B
$12.23B
$5.32B
2025
$14.34B
$4.50B
$12.24B
$5.82B
Recent Quarterly Revenue & Net Income
Quarter
Revenue
Net Income
Sep 2025
$3.75B
$1.46B
Dec 2025
$3.88B
$845M
Mar 2026
$3.61B
$727M
Jun 2026
$4.29B
$1.30B
Ownership & Float
Insider Ownership
2.1%
Institutional Ownership
93.7%
Short Float
2.5%
% of All Funds Holding
15.05%
Number of Funds Holding
1,324
Current Moving Averages
Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.
Timeframe
SMA
Value
Trend Context
Weekly
10-Week SMA
$758.51
Near-term / short-term trend
Weekly
40-Week SMA
$733.31
Medium-term trend
Weekly
80-Week SMA
$663.95
Cyclical trend (business cycle)
Weekly
200-Week SMA
$778.64
Secular trend (multi-year)
Monthly
10-Month SMA
$735.62
Near-term monthly trend
Monthly
20-Month SMA
$671.18
Medium-term monthly trend
Monthly
40-Month SMA
$777.44
Secular monthly trend
Volume Shelves — Support & Resistance
Trend Edge identifies volume shelves: price zones where historically elevated trading volume
creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative
volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.
Price Level
Type
Volume Ratio
Age
$571.00
support
1.11x
10 months ago
$844.00
resistance
1.48x
21 months ago
$1050.00
resistance
1.61x
22 months ago
$1170.00
resistance
1.22x
23 months ago
Historical Earnings Reactions (127 events)
Timeframe
Avg Return
Median
Win Rate
Best
Worst
Gap
-0.04%
-0.03%
43.31%
9.04%
-7.35%
1 Day
-0.23%
-0.39%
43.31%
9.38%
-13.82%
1 Week
0.00%
-1.22%
42.52%
37.31%
-17.73%
2 Weeks
0.55%
-0.56%
47.24%
59.05%
-21.56%
1 Month
5.28%
2.67%
57.14%
212.86%
-32.59%
Next earnings: October 27, 2026 (44 days away)
Seasonality & Day-of-Week Patterns
Monthly Seasonality
Month
Avg Return
Win Rate
Samples
Jan
3.7%
51.4%
35
Feb
8.7%
42.9%
35
Mar
-4.3%
45.7%
35
Apr
1.4%
45.7%
35
May
5.3%
61.1%
36
Jun
0.7%
44.4%
36
Jul
5.7%
66.7%
36
Aug
2.4%
55.6%
36
Sep
2.3%
45.7%
35
Oct
-0.1%
40.0%
35
Nov
4.6%
54.3%
35
Dec
4.3%
45.7%
35
Day-of-Week Tendencies
Day
Avg Return
Win Rate
Samples
Monday
0.10%
47.3%
1680
Tuesday
0.12%
45.7%
1833
Wednesday
0.20%
48.3%
1829
Thursday
0.08%
47.7%
1795
Friday
0.09%
47.2%
1785
Top Institutional Holders
Institutional holder breakdown coming soon.
Total institutional ownership: 93.7%
Insider Transactions — Smart Summary
Total insider ownership: 2.1%
Founder-led management: Leonard Schleifer (Co-Founder, President, CEO & Co-Chairman), George Yancopoulos (Co-Founder, President, Chief Scientific Officer & Co-Chairman)
Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Regeneron Pharmaceuticals Inc
(REGN) powered by Claude Opus — Anthropic's most capable AI model.
The analysis covers five layers:
technical analysis (near-term, medium-term, cyclical, and secular trend, momentum,
volume shelf support and resistance, breakout and breakdown signals),
qualitative analysis (business model, competitive moat, sector dynamics),
insider sentiment (buy and sell signals from executive and director transactions),
share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and
fundamental analysis (valuation, revenue growth, profit margin, earnings quality).
AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit,
stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward.
Whether you are building a long position, initiating a short, or looking for a reversal setup,
AI Consult identifies the highest-probability signal from the current trend.